Finished product reference
Potassium Chloride
Solution · Oral · 20 mEq/15mL
- List code
- 53272
- Pharmacologic class
- Electrolyte replenisher (potassium salt)
What it is and how it works
Potassium is the principal intracellular cation and is essential for nerve conduction, cardiac and skeletal muscle function and acid–base balance. Potassium chloride replaces potassium and chloride, correcting hypokalaemia and hypochloraemic alkalosis.
Indications
Prevention and treatment of hypokalaemia (e.g. with diuretics, corticosteroids, vomiting or diarrhoea); concentrated injection for addition to intravenous fluids in patients who cannot take oral potassium.
Dosage and administration (summary)
Oral: typically 2–4 g (about 25–50 mmol) daily in divided doses for prevention, higher for treatment, guided by serum potassium. Intravenous: must be diluted and given by slow controlled infusion, usually not exceeding 10–20 mmol/hour except in monitored settings.
Contraindications
Hyperkalaemia, severe renal impairment, untreated Addison’s disease and conditions with impaired potassium excretion; solid oral forms in oesophageal compression or delayed gastrointestinal transit.
Warnings and precautions
Monitor serum potassium and renal function; use with caution with potassium-sparing diuretics, ACE inhibitors and angiotensin II receptor antagonists. Concentrated potassium chloride injection must never be given undiluted or by rapid injection, as this can cause fatal cardiac arrest; modified-release tablets may cause gastrointestinal ulceration.
Pregnancy
May be used in pregnancy when needed to correct potassium deficiency.
Storage and supply
Store below 25 °C.
Source: reference summary prepared from the EU SmPC/EPAR, BNF and WHO Model Formulary. The approved product information in Iran governs.
Other presentations of the same active ingredient
- Capsule, Extended Release · Oral · 600 mg51897
- Injection · Intravenous · 0.15 % · 1000 mL52103
- Injection · Intravenous · 0.15 % · 500 mL52102
- Injection · Intravenous · 0.3 % · 1000 mL52205
- Injection · Intravenous · 0.3 % · 500 mL51572
- Solution · Oral · 40 mEq/15mL53273
- Tablet, Extended Release · Oral · 600 mg7564
Reference information for professional sourcing and registration enquiries, not medical advice or a promotion. Drug information is condensed from US FDA prescribing information (public domain, via openFDA and DailyMed) and does not replace the product’s approved labelling in Iran. Availability, origin and documentation are confirmed per enquiry.
Tell us the quantity, the market and the timing.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.